The Pathogenesis of OSA in People Living With HIV
Obstructive Sleep Apnea
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||The Pathogenesis of OSA in People Living With HIV|
- Upper airway collapsibility (Vpassive) [ Time Frame: Night 2 (Visit 2 - to occur within 6 weeks of enrollment) ]Upper airway collapsibility, as assessed by rapid withdrawal of PAP
- Upper airway muscle responsiveness [ Time Frame: Night 2 (Visit 2 - to occur within 6 weeks of enrollment) ]As assessed by rapid withdrawal of PAP
- Pharyngeal fat pad thickness [ Time Frame: MRI study (Visit 3 - to occur within 6 weeks of enrollment) ]As measured by MRI of the head and neck
|Anticipated Study Start Date:||February 2017|
|Estimated Study Completion Date:||December 2018|
|Estimated Primary Completion Date:||February 2018 (Final data collection date for primary outcome measure)|
Individuals (40 years or older) diagnosed with OSA and using CPAP, also with HIV treated to viral suppression.
Individuals (40 years or older) diagnosed with OSA and using CPAP.
Participants who have sleep apnea and are using positive airway pressure (PAP) with and without HIV will be enrolled if they otherwise meet all the inclusion criteria, and none of the exclusion criteria.
Subjects will undergo two overnight sleep studies (polysomnograms, PSGs) and a MRI scan of the upper airway. The first sleep study will evaluate the severity of sleep disordered breathing and will be identical to a clinical PSG. The second sleep study will measure the physiological traits most important for OSA, such as upper airway anatomy, control of breathing, sleep stability, and upper airway muscle activation. These measurements are performed while subjects sleep using PAP, but the PAP level is adjusted during the night, and the subject's response is measured. The MRI scan will be of the head and neck and will occur during the evening time. Subjects will be encouraged to sleep during this portion of the study, as well.
Please refer to this study by its ClinicalTrials.gov identifier: NCT03064204
|Contact: Robert L Owens, M.D.||(858) email@example.com|
|Contact: Pamela DeYoung, RPSGTfirstname.lastname@example.org|
|United States, California|
|University of California, San Diego||Recruiting|
|San Diego, California, United States, 92093|
|Contact: Robert L Owens, MD 858-657-5258 email@example.com|
|Principal Investigator: Robert L Owens, MD|